Cleerly ISCHEMIA vs ZEUS System

Tool B (ZEUS System) offers a 'wear and forget' patient experience with its Zio patch, enhancing patient compliance and ease of use for long-term monitoring. Its robust HL7-based EHR integration, including specific support for Epic via Aura, streamlines clinical workflows from patient registration to report interpretation. While Tool A (Cleerly ISCHEMIA) provides interactive web-based reports and PowerScribe integration, Tool B's broader patient and system-level usability, particularly its seamless EHR integration, gives it an edge.

Tool A (Cleerly ISCHEMIA) provides a comprehensive, non-invasive '3-in-1 approach' to assess atherosclerosis, stenosis, and ischemia from a single CCTA scan, including non-invasive FFR estimation and detailed plaque characterization. Clinical studies show it significantly reduces the need for further invasive testing and increases the use of preventive medications. While Tool B (ZEUS System) offers high diagnostic yield for arrhythmias, Cleerly ISCHEMIA's ability to provide detailed anatomical and functional insights for CAD from a single non-invasive test represents a more transformative impact on diagnostic pathways and treatment planning.

Both tools have opaque pricing, requiring direct contact for details. However, Tool A (Cleerly ISCHEMIA) has established Category I CPTu00ae codes (75580 for FFR estimation and 75577 for plaque analysis effective 2026) for reimbursement, providing a clear pathway for providers to bill for the service. This transparency in reimbursement, even without specific pricing, offers a stronger value proposition for healthcare systems compared to Tool B (ZEUS System), which, despite being described as 'cost-effective' and having favorable cost-effectiveness study results, lacks specific billing codes in the provided information.

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs. Tool B (ZEUS System) explicitly highlights '450+ integrations inclusive of all major ambulatory EHR systems' and specific integration with Epic via the Aura network, simplifying implementation for large health systems. It also emphasizes a 'highly scalable' and 'highly durable, geographically distributed architecture' with 'redundant systems'. While Tool A (Cleerly ISCHEMIA) integrates with PowerScribe, Tool B's broader EHR integration capabilities and explicit scalability claims make it more ready for diverse enterprise environments.

Tool A (Cleerly ISCHEMIA) demonstrates greater innovation by non-invasively estimating fractional flow reserve (FFR) and providing detailed coronary plaque characterization (volume, type, location) directly from CCTA scans. This capability offers a 'novel care paradigm' by deriving functional insights from an anatomical scan, potentially replacing more invasive or additional stress tests. While Tool B (ZEUS System) leverages AI for long-term arrhythmia detection from wearables, the core concept of continuous ECG monitoring is more established, making Cleerly ISCHEMIA's approach a more disruptive advancement.

Tool B (ZEUS System) provides comprehensive support, including readily available 'Instructions for Use' documents in multiple languages and 24/7 customer support via phone. It also offers a 'Patient Support & FAQs' and a 'Clinical Resource Center' for healthcare professionals. Tool A (Cleerly ISCHEMIA) offers client support via a form for existing users, but lacks the explicit detail on 24/7 availability or the breadth of readily accessible documentation that Tool B provides.